Compare Divis Laboratories with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALKEM LABORATORIES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALKEM LABORATORIES DIVIS LABORATORIES/
ALKEM LABORATORIES
 
P/E (TTM) x 51.1 - - View Chart
P/BV x 11.8 8.9 131.9% View Chart
Dividend Yield % 0.5 0.5 106.9%  

Financials

 DIVIS LABORATORIES   ALKEM LABORATORIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ALKEM LABORATORIES
Mar-16
DIVIS LABORATORIES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,6391,589 103.2%   
Low Rs1,1151,232 90.5%   
Sales per share (Unadj.) Rs186.3417.5 44.6%  
Earnings per share (Unadj.) Rs51.056.3 90.5%  
Cash flow per share (Unadj.) Rs57.364.7 88.6%  
Dividends per share (Unadj.) Rs16.0012.70 126.0%  
Dividend yield (eoy) %1.20.9 129.0%  
Book value per share (Unadj.) Rs261.8292.9 89.4%  
Shares outstanding (eoy) m265.47119.57 222.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.43.4 218.8%   
Avg P/E ratio x27.025.1 107.9%  
P/CF ratio (eoy) x24.021.8 110.2%  
Price / Book Value ratio x5.34.8 109.3%  
Dividend payout %31.422.6 139.2%   
Avg Mkt Cap Rs m365,592168,653 216.8%   
No. of employees `00011.8NA-   
Total wages/salary Rs m5,4239,171 59.1%   
Avg. sales/employee Rs Th4,175.1NM-  
Avg. wages/employee Rs Th457.7NM-  
Avg. net profit/employee Rs Th1,141.8NM-  
INCOME DATA
Net Sales Rs m49,46349,915 99.1%  
Other income Rs m1,5561,645 94.6%   
Total revenues Rs m51,01951,561 98.9%   
Gross profit Rs m18,7188,482 220.7%  
Depreciation Rs m1,6891,006 167.9%   
Interest Rs m35671 5.2%   
Profit before tax Rs m18,5518,451 219.5%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,606 312.8%   
Profit after tax Rs m13,5276,731 201.0%  
Gross profit margin %37.817.0 222.7%  
Effective tax rate %27.119.0 142.5%   
Net profit margin %27.313.5 202.8%  
BALANCE SHEET DATA
Current assets Rs m46,50127,062 171.8%   
Current liabilities Rs m8,46815,324 55.3%   
Net working cap to sales %76.923.5 327.0%  
Current ratio x5.51.8 311.0%  
Inventory Days Days13167 196.7%  
Debtors Days Days8641 208.0%  
Net fixed assets Rs m25,79712,610 204.6%   
Share capital Rs m531239 222.0%   
"Free" reserves Rs m68,96234,490 200.0%   
Net worth Rs m69,49335,027 198.4%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m80,38354,387 147.8%  
Interest coverage x531.013.6 3,903.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 67.0%   
Return on assets %16.913.6 124.0%  
Return on equity %19.519.2 101.3%  
Return on capital %26.724.9 107.6%  
Exports to sales %012.9 0.0%   
Imports to sales %24.63.1 798.4%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs m12,1871,540 791.2%   
Fx inflow Rs m41,2386,563 628.3%   
Fx outflow Rs m12,4053,012 411.9%   
Net fx Rs m28,8333,552 811.8%   
CASH FLOW
From Operations Rs m9,5437,259 131.5%  
From Investments Rs m-6,8541,864 -367.7%  
From Financial Activity Rs m-2,459-9,273 26.5%  
Net Cashflow Rs m230-150 -153.1%  

Share Holding

Indian Promoters % 52.0 66.9 77.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 33.1 35.6%  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 0.0 -  
Shareholders   31,796 68,381 46.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Smallcap Stocks Outperform(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended marginally lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 22, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - VENUS REMEDIES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS